Erlangen

• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) in Subjects with Fuchs Dystrophy Ended
  2022-502643-35-00 5 2023-08-09 Fuchs Endothelial Corneal Dystrophy
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) The … Ended
  2024-513329-22-00 7 2023-07-20 Lupus Nephritis
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501753-36-00 5 2023-06-02 Hidradenitis Suppurativa
• Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended
  2022-501586-50-00 5 2023-05-15 Atopic Dermatitis
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A Study to Investigate the Safety and Effectiveness of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial … Ended
  2024-511752-40-00 5 2023-05-05 Fuchs Endothelial Corneal Dystrophy
• An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended
  2022-501850-12-00 4 2023-03-15 Psoriasis
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis … Ended
  2022-500424-30-00 4 2022-12-28 Parkinson’s disease
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended
  2024-512856-40-00 5 2022-09-21 Giant Cell Arteritis
• A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis ses … Ended
  2023-508324-35-00 5 2022-08-19 Apheresis
• Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511069-12-00 5 2022-07-28 Sjögren’s Syndrome
• A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR) Ended
  2024-517406-29-00 4 2022-07-26 Polymyalgia rheumatica (PMR)
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B … Ended
  2023-504795-20-00 3 2022-05-20 Relapsed/Refractory Aggressive Mature B-cell Neoplasms
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended
  2024-512639-58-00 7 2022-05-07 Solid Tumors
• U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing Ended
  2024-512669-15-00 6 2022-03-24 Psoriatic arthritis
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma

Showing 337–360 of 382 trials